Glycated hemoglobin predicts overall and cardiovascular mortality in non-diabetic hemodialysis patients / Ebru Sevinc Ok, Gulay Asci, Huseyin Toz, Eberhard Ritz, Fatih Kircelli, Mehmet Sukru Sever, Mehmet Ozkahya, Savas Sipahi, Hamad Dheir, Devrim Bozkurt, Ziya Omer, Osman Z. Sahin, Muhittin Ertilav, Ercan Ok
AIMS: Besides diabetic patients, glycated hemoglobin (HbA1c) levels have been reported to predict mortality in non-diabetics patients. However, the importance of HbA1c levels in non-diabetic hemodialysis patients still remains unknown. Thus, we aimed to prospectively investigate the impact of HbA1c on all-cause and cardiovascular mortality in a large group of prevalent non-diabetic hemodialysis patients. - METHODS: HbA1c was measured quarterly in 489 non-diabetic prevalent hemodialysis patients. Overall and cardiovascular mortality were evaluated over a 3 year follow-up. - RESULTS: Mean HbA1c level was 4.88 ± 0.46% (3.5 - 6.9%). During the 28.3 ± 10.6 months follow-up period, 67 patients (13.7%) died; 31 from cardiovascular causes. In Kaplan-Meier analysis, patients in the lowest (< 4.69%) and highest HbA1c (> 5.04%) tertiles had poorer overall survival compared to the middle HbA1c tertile (p < 0.001). Adjusted Cox-regression analysis revealed that the highest HbA1c tertile was associated with both overall (HR = 3.60, 95% CI 1.57 - 8.27, p = 0.002) and cardiovascular (HR = 6.66, 95% CI 1.51 - 29.4; p = 0.01) mortality. Also, low HbA1c levels tended to be associated with overall mortality (HR = 2.26, 95% CI 0.96 - 5.29, p = 0.06). - CONCLUSION: Upper normal HbA1c levels are independently associated with cardiovascular and overall mortality in non-diabetic hemodialysis patients, whereas lower HbA1c levels are not..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
September 2014 2014 |
---|---|
Erschienen: |
September 2014 |
Enthalten in: |
Zur Gesamtaufnahme - volume:82 |
---|---|
Enthalten in: |
Clinical nephrology - 82(2014), 3, Seite 173-180 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ok, Ebru Sevinc [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Gesehen am 16.02.2021 |
---|
Umfang: |
8 |
---|
doi: |
10.5414/cn108251 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
1748460765 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | 1748460765 | ||
003 | DE-627 | ||
005 | 20230426072750.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210216s2014 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.5414/cn108251 |2 doi | |
035 | |a (DE-627)1748460765 | ||
035 | |a (DE-599)KXP1748460765 | ||
035 | |a (OCoLC)1341393448 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
100 | 1 | |a Ok, Ebru Sevinc |e verfasserin |0 (DE-588)1219311383 |0 (DE-627)1735250872 |4 aut | |
245 | 1 | 0 | |a Glycated hemoglobin predicts overall and cardiovascular mortality in non-diabetic hemodialysis patients |c Ebru Sevinc Ok, Gulay Asci, Huseyin Toz, Eberhard Ritz, Fatih Kircelli, Mehmet Sukru Sever, Mehmet Ozkahya, Savas Sipahi, Hamad Dheir, Devrim Bozkurt, Ziya Omer, Osman Z. Sahin, Muhittin Ertilav, Ercan Ok |
264 | 1 | |c September 2014 | |
300 | |a 8 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Gesehen am 16.02.2021 | ||
520 | |a AIMS: Besides diabetic patients, glycated hemoglobin (HbA1c) levels have been reported to predict mortality in non-diabetics patients. However, the importance of HbA1c levels in non-diabetic hemodialysis patients still remains unknown. Thus, we aimed to prospectively investigate the impact of HbA1c on all-cause and cardiovascular mortality in a large group of prevalent non-diabetic hemodialysis patients. - METHODS: HbA1c was measured quarterly in 489 non-diabetic prevalent hemodialysis patients. Overall and cardiovascular mortality were evaluated over a 3 year follow-up. - RESULTS: Mean HbA1c level was 4.88 ± 0.46% (3.5 - 6.9%). During the 28.3 ± 10.6 months follow-up period, 67 patients (13.7%) died; 31 from cardiovascular causes. In Kaplan-Meier analysis, patients in the lowest (< 4.69%) and highest HbA1c (> 5.04%) tertiles had poorer overall survival compared to the middle HbA1c tertile (p < 0.001). Adjusted Cox-regression analysis revealed that the highest HbA1c tertile was associated with both overall (HR = 3.60, 95% CI 1.57 - 8.27, p = 0.002) and cardiovascular (HR = 6.66, 95% CI 1.51 - 29.4; p = 0.01) mortality. Also, low HbA1c levels tended to be associated with overall mortality (HR = 2.26, 95% CI 0.96 - 5.29, p = 0.06). - CONCLUSION: Upper normal HbA1c levels are independently associated with cardiovascular and overall mortality in non-diabetic hemodialysis patients, whereas lower HbA1c levels are not. | ||
650 | 4 | |a Adult | |
650 | 4 | |a Aged | |
650 | 4 | |a Biomarkers | |
650 | 4 | |a Cardiovascular Diseases | |
650 | 4 | |a Cause of Death | |
650 | 4 | |a Chi-Square Distribution | |
650 | 4 | |a Female | |
650 | 4 | |a Glycated Hemoglobin A | |
650 | 4 | |a Humans | |
650 | 4 | |a Kaplan-Meier Estimate | |
650 | 4 | |a Male | |
650 | 4 | |a Middle Aged | |
650 | 4 | |a Multivariate Analysis | |
650 | 4 | |a Predictive Value of Tests | |
650 | 4 | |a Proportional Hazards Models | |
650 | 4 | |a Prospective Studies | |
650 | 4 | |a Renal Dialysis | |
650 | 4 | |a Renal Insufficiency, Chronic | |
650 | 4 | |a Risk Assessment | |
650 | 4 | |a Risk Factors | |
650 | 4 | |a Time Factors | |
650 | 4 | |a Turkey | |
700 | 1 | |a Asci, Gulay |e verfasserin |4 aut | |
700 | 1 | |a Toz, Huseyin |e verfasserin |4 aut | |
700 | 1 | |a Ritz, Eberhard |d 1938-2023 |e verfasserin |0 (DE-588)106673386 |0 (DE-627)610528866 |0 (DE-576)311552501 |4 aut | |
700 | 1 | |a Kircelli, Fatih |e verfasserin |4 aut | |
700 | 1 | |a Sever, Mehmet Sukru |e verfasserin |4 aut | |
700 | 1 | |a Ozkahya, Mehmet |e verfasserin |4 aut | |
700 | 1 | |a Sipahi, Savas |e verfasserin |4 aut | |
700 | 1 | |a Dheir, Hamad |e verfasserin |4 aut | |
700 | 1 | |a Bozkurt, Devrim |e verfasserin |4 aut | |
700 | 1 | |a Omer, Ziya |e verfasserin |4 aut | |
700 | 1 | |a Sahin, Osman Z. |e verfasserin |4 aut | |
700 | 1 | |a Ertilav, Muhittin |e verfasserin |4 aut | |
700 | 1 | |a Ok, Ercan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical nephrology |d Deisenhofen, Munich : Dustri-Verl. Feistle, 2002 |g 82(2014), 3, Seite 173-180 |h Online-Ressource |w (DE-627)320498875 |w (DE-600)2011960-4 |w (DE-576)356321711 |7 nnns |
773 | 1 | 8 | |g volume:82 |g year:2014 |g number:3 |g pages:173-180 |g extent:8 |
856 | 4 | 0 | |u https://doi.org/10.5414/cn108251 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u https://www.dustri.com/nc/article-response-page.html?artId=12547&doi= |x Verlag |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ILN_2013 | ||
912 | |a ISIL_DE-16-250 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4306 | ||
936 | u | w | |d 82 |j 2014 |e 3 |h 173-180 |g 8 |
951 | |a AR | ||
952 | |d 82 |j 2014 |e 3 |h 173-180 |g 8 | ||
980 | |2 2013 |1 01 |x DE-16-250 |b 3856033335 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 16-02-21 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2014 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_14 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_8 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1434967360 |a Ritz, Eberhard | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416740783 |a Medizinische Universitätsklinik und Poliklinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_4 |